Results 271 to 280 of about 215,802 (313)

Cyclin-dependent-kinase-4-inhibitors/cyclin-dependent-kinase-6-inhibitors/fluconazole

Reactions Weekly, 2023
openaire   +1 more source

Cyclin-dependent-kinase-4-inhibitors/cyclin-dependent-kinase-6-inhibitors/fulvestrant

Reactions Weekly, 2023
openaire   +1 more source

Cyclin‐dependent kinase inhibitors for treating cancer

Medicinal Research Reviews, 2001
AbstractCyclin dependent kinases (Cdks) are essential enzymes for the control of cell cycle progression. Inhibitors of cyclin‐dependent kinases are anticipated to possess therapeutic utility against a wide variety of proliferative diseases, especially cancer. The field of published small molecule Cdk inhibitors is briefly reviewed here as background to
openaire   +2 more sources

Cyclin-Dependent Kinase Inhibitor–Associated Thromboembolism

JAMA Oncology, 2019
Sven R, Olson, Thomas G, DeLoughery, Joseph J, Shatzel   +2 more
openaire   +2 more sources

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment

Cell, 2023
Marlies Meisel
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

Cyclin-Dependent Kinase Inhibitors and Human Cancer

1998
As tumor suppressor candidates, cyclin-dependent kinase (CDK) inhibitors have a simple, aesthetic quality. They act directly on the mechanism that drives cells through mitosis and DNA replication. Elimination of CDK inhibitor activity, by mutation for instance, should release CDKs from this form of regulation and remove one of the restraints on cell ...
openaire   +2 more sources

Assays for Cyclin-Dependent Kinase Inhibitors

2003
Adrian M, Senderowicz, Tyler, Lahusen
openaire   +2 more sources

Cyclin-dependent-kinase-inhibitors/exemestane

Reactions Weekly, 2021
openaire   +1 more source

Chemical inhibitors of cyclin-dependent kinases

1997
L, Meijer, S H, Kim
openaire   +2 more sources